Nurix Therapeutics (NRIX) Equity Ratio: 2019-2025
Historic Equity Ratio for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to 0.71.
- Nurix Therapeutics' Equity Ratio fell 2.90% to 0.71 in Q3 2025 from the same period last year, while for Aug 2025 it was 0.71, marking a year-over-year decrease of 2.90%. This contributed to the annual value of 0.79 for FY2024, which is 39.64% up from last year.
- Latest data reveals that Nurix Therapeutics reported Equity Ratio of 0.71 as of Q3 2025, which was down 5.84% from 0.76 recorded in Q2 2025.
- Over the past 5 years, Nurix Therapeutics' Equity Ratio peaked at 0.79 during Q4 2024, and registered a low of 0.54 during Q1 2024.
- For the 3-year period, Nurix Therapeutics' Equity Ratio averaged around 0.71, with its median value being 0.74 (2023).
- In the last 5 years, Nurix Therapeutics' Equity Ratio dropped by 27.11% in 2024 and then spiked by 44.88% in 2025.
- Quarterly analysis of 5 years shows Nurix Therapeutics' Equity Ratio stood at 0.72 in 2021, then climbed by 1.50% to 0.73 in 2022, then declined by 22.63% to 0.56 in 2023, then spiked by 39.64% to 0.79 in 2024, then decreased by 2.90% to 0.71 in 2025.
- Its Equity Ratio stands at 0.71 for Q3 2025, versus 0.76 for Q2 2025 and 0.78 for Q1 2025.